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Abstract
Objective: Our goal was to assess
the association between the use of
nasal continuous positive airway
pressure (NCPAP) vs. conventional
ventilation (CV) in premature infants
and its effects on: 1) growth in the
NICU and at follow up visits
2) neurodevelopmental outcomes
measured by Bayley Infant
Neurodevelopmental Screener (BINS)
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3) the incidence of retinopathy of
prematurity (ROP) and chronic lung
disease (CLD).
Methods: A retrospective chart
review of two groups of NICU patients
was conducted. The ﬁrst group was
from 1/1999 – 12/2000 (n=140) and
was managed by CV. The second
group (n=168) was from 1/2003 –
12/2004 and was managed primarily
by NCPAP. Categorical variables were
analyzed using Pearson Chi Square.
Mean numerical values were analyzed
with the student t-test.
Results: There was no statistical
difference between the groups in
regard to 15 demographic and
interventional variables. There were
signiﬁcant differences between the two
groups in CLD (p<0.05) and ROP
(p<0.01), mean weight at one month
(p<0.05), 9-12 months (p<0.01) and
15-18 months (p<0.01), length at 4-6
months (p<0.05), 9-12 months (p<0.05),
15-18 months (p<0.01), and 2 years
(p=.05), and in BINS scores at 9-12
months (p<0.01) and 15-18 months
(p<0.01).
Conclusions: Managing babies
with NCPAP therapy when compared
with CV, signiﬁcantly increased the
weight at one month which was
sustained at the 9-12 month and 15-18
month visits, increased length at all
follow up visits, increased BINS scores
at the 9-12 month and 15-18 month
visits, and decreased the incidence of
ROP and CLD.

Introduction
Studies over the past twenty
years have shown an improvement
in neonatal mortality but
unfortunately have not shown
the same for morbidity. Fanaroff
et. al prospectively studied the
mortality and morbidity of infants
501-1500 grams from 1990 to 2002
at twelve centers of the National
Institute of Child Health and Human
Development Neonatal Research
Network. While it was found that
mortality decreased in subsequent
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cohorts, survival with one or more
morbidities increased slightly. In the
EPIcure Study in the UK (2000), of
infants 23-26 weeks, fewer than half
were neurologically intact. Similar
neurodevelopmental outcomes have
been reported in the US in studies
by Hack and Fanaroff (2000) and
Vohr, Wright, and Dusick (2000).
While these studies have considered
effects of such treatment modalities
as antenatal and postnatal steroids
and antibiotics, to our knowledge no
one has studied the effect of NCPAP
on neurodevelopmental outcomes.
Use of NCPAP in premature
infants has gained favor. Children’s
Hospital of New York – Columbia
University has become known for the
use of NCPAP which has resulted in
significantly lower rates of chronic
lung disease. The association of
decreased chronic lung disease with
NCPAP was reported by Avery et. al,
and has been confirmed in a survey
of 11 other American centers. While
NCPAP is now being used more
routinely, there still remain questions
and the body of knowledge
regarding its use is still growing.
One issue is it is very resourceintensive, requiring skilled and
experienced staff to ensure success
of the treatment. Additional research
regarding benefits of NCPAP will
increase universal acceptance and
make centers less likely to stop
NCPAP and begin conventional
ventilation with onset of apnea,
skin irritation or nurse frustration
with correct NCPAP positioning.
Some studies have also shown an
increased risk of pneumothorax
and necrotizing enterocolitis.8
Most importantly regarding the
need for our research is the fact
that recent studies acknowledge
long term consequences including
neurodevelopmental outcomes
of CPAP remain undetermined
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Table 1. Group Demographic and Intervention Variables.
Variable
Male (%)

CV

CPAP

p Value

49

52

0.51

Gestational Age (mean)

29.5

29.3

0.40

Birth Weight (mean)

1140

1148

0.79

Birth Head Circ (mean)

26.5

26.5

0.88

Birth Length (mean)

37.2

37.6

0.34

1 min Apgar (mean)

6.2

6.3

0.82

5 min Apgar (mean)

7.7

7.8

0.76

10 min Apgar (mean)

7.2

7.2

0.99

SGA (%)

27.5

21.4

0.21

10

7.7

0.49

Chorioamnionitis (%)
Nosocomial Infection (%)

31

28

0.51

57.1

64

0.24

Transports (%)

15

17

0.59

22 Calorie Formula (%)

43

51

0.83

Early Intervention (%)

62

64

0.92

Antenatal Steroids (%)

and need to be monitored.
Research regarding improved
growth with the use of NCPAP is
very limited. Geary et. al. found
the introduction of surfactant at
delivery followed by immediate
extubation to CPAP, decreased
oxygen exposure, and that giving
early parenteral amino acids in
extremely low birth weight infants
was associated with improvements
in growth and morbidity. Our NICU
transitioned to NCPAP for the
primary respiratory support system
of premature newborns in January
2002. Within the first year, our
observations suggested that our
incidence of chronic lung disease
had significantly declined. Over
the next five years it was noted
anecdotally that our babies seemed
to achieve catch up in their growth
and development faster than they
had when managed by CV. We
hypothesized that a retrospective
review would show improved growth
and improved BINS scores in our
babies managed with NCPAP. At the
same time we also opted to look at
the incidence of ROP and CLD in
our NICU during these two different
treatment modes, expecting that
they would decrease with NCPAP.

16

Patients and Methods
A retrospective chart review of
two groups of NICU patients < 1500
grams was conducted. The first
group was from January 1999 –
December 2000 (n=140) and was
managed by CV. The second group
was from January 2003-December
2004 (n=168) and was managed
primarily by NCPAP. As in other
studies of NCPAP10,13 each baby is
managed individually and if clinical
condition warrants, implementation
of CV is executed. Our data showed
our CV group had a mean of 17.4
days on the ventilator and no
NCPAP days. The NCPAP group
had a mean of 4.5 days on the
ventilator and 19.2 days on NCPAP.
So our NCPAP babies were exposed
to a mean of 12.9 fewer ventilator
days. Excluded from the study were
babies who died or had Grade III or
IV intraventricular hemorrhage. In
order to evaluate the similarity of the
two groups, demographic variables
of gender, gestational age, birth
weight, birth head circumference,
birth length, APGAR scores, size
for gestational age, maternal
chorioamnionitis, nosocomial
infections, antenatal steroid use,
and transport status were compared
between the two groups. Intervention
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variables compared included the
use of high calorie formula and
provision of early intervention
services. Outcome variables
measured included mean weight at
two weeks, one month, 4-6 months,
9-12 months, 15-18 months, and two
years. Mean head circumference
and length were also evaluated at
these intervals excluding two weeks
and one month. Also evaluated
were the percent having CLD
and ROP. CLD was defined as an
oxygen requirement at 36 weeks
post menstrual age. Finally mean
Bayley Infant Neurodevelopmental
Screening (BINS) percentage scores
at 4-6 months, 9-12 months, 1518 months, and two years were
calculated. Because there are a
different number of BINS criteria at
the various ages, a percentage of
criteria met was used rather than
a raw score. Categorical values
were analyzed using Pearson Chi
Square. Mean numerical values
were analyzed with the student
t-test. These parametric tests were
selected because they have higher
statistical power than non parametric
tests and we assumed that our NICU
population has a normal distribution.

Results
There was no statistically
significant difference between the
two groups in regard to any of the
fifteen demographic and intervention
variables. These variables, which
were compared to assure similarity
of the two groups, included gender,
gestational age, birth weight, birth
head circumference, birth length,
Apgar scores, number of small for
gestational age babies, maternal
chorioamnionitis, nosocomial
infections, antenatal steroid use,
percentage of babies transported
in, use of high calorie formula,
and early intervention therapies. It
should be noted that the % SGA
was 27.5% in the CV group and
only 21.4% in the CPAP group.
While this did not achieve statistical
significance, it may have had an
impact on the outcomes studied. The
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data and p values related to these
variables are depicted in Table I.
Additional assurance of
similarity between the two groups
is derived from the fact that the
same neonatologists were present
during both time frames. No
changes were made in feeding
protocols, antibiotic usage, or
parental interaction policies
between the two time periods.
The NCPAP group demonstrated
significantly improved growth and
development. The mean one month
weight in the NCPAP group was
1449 grams as compared to 1340
grams in the CV group (p<0.05).
At the 9-12 month NICU follow up
clinic visit mean weight was 9.0 kg
in the NCPAP group and 8.3 kg in
the CV group (p<0.01). Finally at
the 15-18 month visit mean weight
in the NCPAP group was 10.6
kg as compared to 9.6 kg in the
CV group (p<0.01). While weight
was also greater in the NCPAP
group at 2 weeks, 4-6 months,
and 2 years, these values were
not statistically significant. Linear
growth was significantly greater
at all measured intervals. At 4-6
months, the NCPAP mean length
was 64.4 centimeters as compared
to 58.2 centimeters in the CV group
(p<0.05). Similar differences were
noted at 9-12 months (NCPAP
= 73 centimeters, CV = 71.5
centimeters, p<0.05), 15-18 months
(NCPAP = 81.3 centimeters, CV =
78.2 centimeters (p<0.01), and 2
years (NCPAP = 88.5 centimeters,
CV = 85 centimeters, p=.05).
Head circumference was also
monitored and no difference was
found between the two groups.
The percentage of items
successfully achieved on the BINS
was greater in the NCPAP group
at all follow up visits and was
statistically significant at the 9-12
month visit (NCPAP = .91, CV = .77,
p<0.01) and the 15-18 month visit
(NCPAP = .84, CV = .69, p<0.01).
It should be noted that the number
of babies in the study decreased
at each subsequent visit. This
occurred as some were lost to follow

up and others were discharged
from the clinic after achieving catch
up in growth and development.
See Table 2-4 for full data sets
regarding growth and BINS scores.
Incidence of CLD was 18.5% in the
NCPAP group and 30% in the CV
group (p<0.05). Incidence of ROP
was 6% in the NCPAP group and
15% in the CV group (p<0.01).

Discussion
As advancements in the field of
neonatology continue to lead to
decreased mortality, it is imperative
that the study of neurodevelopmental
effects of various treatment
modalities be ongoing. Just as
practice changed regarding the
use of postnatal steroids which
have been linked to worsened
neurodevelopmental outcomes,
we must continue to strive toward
better interventions, with improved
outcomes. It has already been

established that NCPAP decreases
the incidence of CLD and this was
confirmed in our NICU as well. As
was reported in the Geary study7
as well as ours, it appears NCPAP
has additional benefits of improved
growth. Perhaps these babies do not
have to utilize as many calories for
repair of lung damage related to CLD
and for increased work of breathing,
thereby enabling better growth.
What are possible explanations for
the improvements in BINS scores?
It could be directly related to their
improved growth. Hack (1982)
found that preterm infants who
maintain good growth velocity and
demonstrate catch up growth also
do better neurodevelopmentally.
Nutrition has been found to impact
long term growth and development
(Adamkin, 2008). Or perhaps it may
be related to NCPAPs effect on CLD.
Infants with CLD have poorer growth
and disruption of normal brain

Tables II-IV. Comparisons of Weight, Length, and Bailey Infant
Neurodevelopmental Screener scores.
Table 2. Weight
CV

CPAP

p Value

2 wks (gm)

Age

1170

1194

0.45

1 month (gm)

1340

1449

0.02

4 months (kg)

6.1

(n=87)

6.4

(n=92)

0.15

9 months (kg)

8.3

(n=66)

9.0

(n=59)

0.0009

15 months (kg)

9.6

(n=37)

10.6

(n=48)

0.002

11.2

(n=24)

12.1

(n=12)

0.16

2 years (kg)
Table 3. Length
Age

CV

CPAP

p Value

4 months (cm)

58.2

(n=87)

64.4

(n=92)

0.02

9 months (cm)

71.5

(n=66)

73

(n=59)

0.0009

15 months (cm)

78.2

(n=36)

81.3

(n=48)

0.002

2 years (cm)

85

(n=24)

88.5

(n=12)

0.05

Table IV. BINS
Age

CV

CPAP

p Value

4 months

0.87

(n=85)

0.89

(n=92)

0.29

9 months

0.77

(n=66)

0.91

(n=59)

0.000

15 months

0.69

(n=37)

0.84

(n=48)

0.006

2 years

0.66

(n=22)

0.74

(n=11)

0.42
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development (Chiriboga, 2003).
CLD has been found to increase
the risk for later neurobehavioral
impairment (Short, 2003). In infants
less than 1500 gms 15% of those
with CLD had CP compared with
only 3-4% of those without CLD
having CP (Skidmore, Rivers, and
Hack, 1990). Anecdotally, our nurses
report parents feel more comfortable
holding and interacting with babies
on NCPAP than those who are
intubated. Therefore NCPAP
babies may receive more positive
stimulation because caregivers do
not fear an accidental extubation.
A weakness of our study was
the decreasing numbers we had at
each follow up clinic visit. By the 2
year visit we only had 24 patients in
the CV group and 12 in the NCPAP
group. This of course lowered the
power of our statistical analysis
and contributed to the fact that the
increased weight and increased
BINS scores at this visit did not have
statistical significance. However,
a positive twist may be that part of
the reason these numbers lowered
is that we discharge babies prior
to 2 years if they have achieved
catch up. Even though we started
out with more in the NCPAP group
(168) than in the CV group (140),
by the two year visit there were
twice as many in the CV group.
Some of the decreased numbers
are the result of babies being lost
to follow up but the majority is due
to babies having achieved catch up
in growth and development. Thus
more babies in the NCPAP group
no longer needed our services.
Weight was not consistently
significantly higher at every interval.
Perhaps at two weeks, enough
time had not elapsed to yet show
significance. Lack of significance
at the 4-6 month visit is harder to
explain as to why we would see
significance before this at 1 month
and afterward at 9-12 and 15-18
months. However linear growth
difference was significant at every
measurement (even with the small
numbers at the 2 year visit) and this
is generally considered to be a better
indicator of appropriate nutrition.
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The elevation in the NCPAP BINS
scores at the 4-6 month visit
was not significant. This seems
intuitive as not much is required
developmentally at this age. As with
all retrospective studies, association
is not proof of causality. In order to
truly compare the effects of NCPAP
vs. CV on growth and development,
a randomized, prospective
study would be necessary.
A strength of our study is the strong
similarity of the two groups. This is
evident statistically, having found no
difference in any of the demographic
or intervention variables. Similarity
of treatment protocols was also
improved by the fact that the same
neonatologists were practicing
during both time periods. No
changes were made in feeding
protocols during the management of
either cohort.

Conclusion
The use of NCPAP in premature
infants has definitely been shown
to decrease CLD. If it in fact also
improves growth and development
this could contribute to reduced
morbidity in this vulnerable group.
In our study NCPAP therapy
in premature babies when
compared with CV significantly:
• Increased weight at one month
which was sustained at the 9-12
month and 15-18 month visits.
• Increased BINS scores
at the 9-12 month and
15-18 month visits.
• Improved linear growth
at all follow up visits.
• Decreased the occurrence
of CLD and ROP.
We also noted that a greater
percentage of the NCPAP babies
were discharged earlier from
the NICU follow up clinic due to
complete catch up. Further study is
needed to investigate the benefits
of NCPAP use for smaller, sicker
babies and those with high risk for
neurodevelopmental abnormalities.
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